Toxicology, Pathology and Biodistribution Core (TPB Core)

毒理学、病理学和生物分布核心(TPB 核心)

基本信息

  • 批准号:
    7982610
  • 负责人:
  • 金额:
    $ 9.59万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-01 至 2015-08-31
  • 项目状态:
    已结题

项目摘要

The Toxicology, Pathology, and Biodistribution Core will provide qualitative and quanfitative assessment of the movement and deposition of mNPs in ail major organ tissues as well as individual cells in specific settings. The TPB core will also provide dedicated and comprehensive pharmacokinetic (Lewis), human and animal pathology/pathophysiology (Memoli and Hoopes) and TEM/SEM (Daghlian) expertise for potential cellular and/or tissue change resulfing from the mNPs (iron, coafings, targefing peptides, fluorescent probes etc and/or the alternafing magnetic field (AMF) exposure. Since it is the primary goal of the entire DCCNE application to opfimize methods for the observation and selectively delivery of mNP/lron to cancer cells for subsequent cytotoxic excitation, the assessment and quantification of iron levels in cells and fissues (Prussian Blue histomorphometry and ICP-MS) and the resultant pathologic effects in the tumor and normal fissues, is of paramount importance. The TPB Core will be a central partcipant in the determination ofthe relafive ability ofthe various NP physical parameters, coatings, internalizing vs noninternalizing ScFv peptides to selectively target mNP /iron to cancer cells in vitro and in vivo (Project 1). In addition, TEM will allow an accurate assessment of the volume and anatomic location of the various NPs with respect to effective excitation and cytotoxicity. TPB assessments will determine which peptides have the most targeting promise for future use in preclinical in vivo ovarian and breast tumor models (Projects 2 and 3). In Project 2, the TPB will play an essential role determining the accuracy and sensitivity ofthe mNP in vivo imaging techniques. Pathologic co-registration and validation of changes observed by noninvasive imaging techniques such as optical spectroscopy and MRI remains the gold standard for determining the sensitivity and reliability of new imaging techniques. In Project 3, the use of ICP-MS and Prussian Blue histomorphometry mNP /iron quantificafion techniques will allow investigators to determine the absolute role of mNP/lron content in tumor treatment efficacy studies. In Project 4, the TPB Core will be important in determining the level of iron that is taken up by the ovarian cancer dendritic cells, cancer cells and other abdominal tissues that are exposed to the ip delivered mNPs. Since the targeted NP exposure field, in this cancer model, is large, there Is a risk of normal tissue injury. Pathologic assessment of these mice will be extremely important for safety and the understanding of toxicity/efficacy.
毒理学、病理学和生物分布核心将对mNPs在所有主要器官组织以及特定环境下的单个细胞中的运动和沉积进行定性和定量评估。TPB核心还将提供专门和全面的药代动力学(Lewis)、人类和动物病理学/病理生理学(Memoli和Hoopes)和TEM/SEM (Daghlian)专业知识,以研究mNPs(铁、涂层、靶向肽、荧光探针等)和/或交变磁场(AMF)暴露导致的潜在细胞和/或组织变化。由于整个DCCNE应用的主要目标是优化观察和选择性递送mNP/铁到癌细胞以进行随后的细胞毒性激发的方法,因此评估和定量细胞和组织中的铁水平(普鲁士蓝组织形态学和ICP-MS)以及由此产生的肿瘤和正常组织中的病理效应至关重要。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LIONEL David LEWIS其他文献

LIONEL David LEWIS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LIONEL David LEWIS', 18)}}的其他基金

7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors
7HP349,一种整合素激活剂,用于治疗抗 PD-1 耐药实体瘤患者
  • 批准号:
    10761171
  • 财政年份:
    2023
  • 资助金额:
    $ 9.59万
  • 项目类别:
Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors
开发 7HP349,一种口服整合素激活剂,可增强对免疫检查点抑制剂的治疗反应
  • 批准号:
    10261525
  • 财政年份:
    2020
  • 资助金额:
    $ 9.59万
  • 项目类别:
CLINICAL PHARMACOLOGY SHARED RESOURCE
临床药理学共享资源
  • 批准号:
    7944619
  • 财政年份:
    2009
  • 资助金额:
    $ 9.59万
  • 项目类别:
PROTOCOL REVIEW AND MONITORING SYSTEM
方案审查和监测系统
  • 批准号:
    7944683
  • 财政年份:
    2009
  • 资助金额:
    $ 9.59万
  • 项目类别:
Clinical Molecular
临床分子
  • 批准号:
    6989452
  • 财政年份:
    2004
  • 资助金额:
    $ 9.59万
  • 项目类别:
Clinical Pharmacology (CP)
临床药理学(CP)
  • 批准号:
    10554245
  • 财政年份:
    1997
  • 资助金额:
    $ 9.59万
  • 项目类别:
Clinical Pharmacology (CP)
临床药理学(CP)
  • 批准号:
    8804008
  • 财政年份:
    1997
  • 资助金额:
    $ 9.59万
  • 项目类别:
Clinical Pharmacology (CP)
临床药理学(CP)
  • 批准号:
    10311226
  • 财政年份:
    1997
  • 资助金额:
    $ 9.59万
  • 项目类别:
Protocol Review and Monitoring System (PRMS)
方案审查和监控系统 (PRMS)
  • 批准号:
    10554303
  • 财政年份:
    1997
  • 资助金额:
    $ 9.59万
  • 项目类别:
Protocol Review and Monitoring System (PRMS)
方案审查和监控系统 (PRMS)
  • 批准号:
    10311241
  • 财政年份:
    1997
  • 资助金额:
    $ 9.59万
  • 项目类别:

相似海外基金

CAREER: Blessing of Nonconvexity in Machine Learning - Landscape Analysis and Efficient Algorithms
职业:机器学习中非凸性的祝福 - 景观分析和高效算法
  • 批准号:
    2337776
  • 财政年份:
    2024
  • 资助金额:
    $ 9.59万
  • 项目类别:
    Continuing Grant
CAREER: From Dynamic Algorithms to Fast Optimization and Back
职业:从动态算法到快速优化并返回
  • 批准号:
    2338816
  • 财政年份:
    2024
  • 资助金额:
    $ 9.59万
  • 项目类别:
    Continuing Grant
CAREER: Structured Minimax Optimization: Theory, Algorithms, and Applications in Robust Learning
职业:结构化极小极大优化:稳健学习中的理论、算法和应用
  • 批准号:
    2338846
  • 财政年份:
    2024
  • 资助金额:
    $ 9.59万
  • 项目类别:
    Continuing Grant
CRII: SaTC: Reliable Hardware Architectures Against Side-Channel Attacks for Post-Quantum Cryptographic Algorithms
CRII:SaTC:针对后量子密码算法的侧通道攻击的可靠硬件架构
  • 批准号:
    2348261
  • 财政年份:
    2024
  • 资助金额:
    $ 9.59万
  • 项目类别:
    Standard Grant
CRII: AF: The Impact of Knowledge on the Performance of Distributed Algorithms
CRII:AF:知识对分布式算法性能的影响
  • 批准号:
    2348346
  • 财政年份:
    2024
  • 资助金额:
    $ 9.59万
  • 项目类别:
    Standard Grant
CRII: CSR: From Bloom Filters to Noise Reduction Streaming Algorithms
CRII:CSR:从布隆过滤器到降噪流算法
  • 批准号:
    2348457
  • 财政年份:
    2024
  • 资助金额:
    $ 9.59万
  • 项目类别:
    Standard Grant
EAGER: Search-Accelerated Markov Chain Monte Carlo Algorithms for Bayesian Neural Networks and Trillion-Dimensional Problems
EAGER:贝叶斯神经网络和万亿维问题的搜索加速马尔可夫链蒙特卡罗算法
  • 批准号:
    2404989
  • 财政年份:
    2024
  • 资助金额:
    $ 9.59万
  • 项目类别:
    Standard Grant
CAREER: Efficient Algorithms for Modern Computer Architecture
职业:现代计算机架构的高效算法
  • 批准号:
    2339310
  • 财政年份:
    2024
  • 资助金额:
    $ 9.59万
  • 项目类别:
    Continuing Grant
CAREER: Improving Real-world Performance of AI Biosignal Algorithms
职业:提高人工智能生物信号算法的实际性能
  • 批准号:
    2339669
  • 财政年份:
    2024
  • 资助金额:
    $ 9.59万
  • 项目类别:
    Continuing Grant
DMS-EPSRC: Asymptotic Analysis of Online Training Algorithms in Machine Learning: Recurrent, Graphical, and Deep Neural Networks
DMS-EPSRC:机器学习中在线训练算法的渐近分析:循环、图形和深度神经网络
  • 批准号:
    EP/Y029089/1
  • 财政年份:
    2024
  • 资助金额:
    $ 9.59万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了